ACRS
insider transactionsAclaris Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-300.0K
0 buy · 300.0K sell
Net value · 90d
-$1.4M
$0 in · $1.4M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
1
0 buy · 300.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
11.6K sh
Own New
-
Exercise·M
Director
—
11.6K sh
Own +35%
-
Exercise·M
Director
$0
11.6K sh
Own New
-
Exercise·M
Director
—
11.6K sh
Own +20%
-
Exercise·M
Director
$0
11.6K sh
Own New
-
Exercise·M
Director
—
11.6K sh
Own +2%
-
Exercise·M
Director
$0
11.6K sh
Own New
-
Exercise·M
Director
—
11.6K sh
Own +53%
-
Exercise·M
Director
$0
11.6K sh
Own New
-
Exercise·M
Director
—
11.6K sh
Own +67%
-
Exercise·M
Director
$0
11.6K sh
Own New
-
Exercise·M
Director
—
11.6K sh
Own +83%
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
42.4K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
42.4K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
42.4K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
42.4K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
42.4K sh
Own New
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
42.4K sh
Own New
-
Exercise·M
Chief Medical Officer
$0
36.4K sh
Own +50%
-
Other·F
Chief Medical Officer
$41.1K
9.3K sh · $4.41
Own -26%
-
Exercise·M
Chief Medical Officer
—
36.4K sh
Own New
-
Sell·S
10% Owner
$1.4M
300.0K sh · $4.53
Own -2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | William D. Humphries | Exercise M | 11.6K | $0 |
| Jun 5, 2026 | William D. Humphries | Exercise M | 11.6K | — |
| Jun 5, 2026 | Christopher P. Molineaux | Exercise M | 11.6K | $0 |
| Jun 5, 2026 | Christopher P. Molineaux | Exercise M | 11.6K | — |
| Jun 5, 2026 | Anand Mehra | Exercise M | 11.6K | $0 |
| Jun 5, 2026 | Anand Mehra | Exercise M | 11.6K | — |
| Jun 5, 2026 | Maxine Gowen | Exercise M | 11.6K | $0 |
| Jun 5, 2026 | Maxine Gowen | Exercise M | 11.6K | — |
| Jun 5, 2026 | Vincent Milano | Exercise M | 11.6K | $0 |
| Jun 5, 2026 | Vincent Milano | Exercise M | 11.6K | — |
| Jun 5, 2026 | Andrew N Schiff | Exercise M | 11.6K | $0 |
| Jun 5, 2026 | Andrew N Schiff | Exercise M | 11.6K | — |
| Jun 4, 2026 | William D. Humphries | Grant A | 11.0K | $0 |
| Jun 4, 2026 | William D. Humphries | Grant A | 42.4K | $0 |
| Jun 4, 2026 | Christopher P. Molineaux | Grant A | 11.0K | $0 |
| Jun 4, 2026 | Christopher P. Molineaux | Grant A | 42.4K | $0 |
| Jun 4, 2026 | Anand Mehra | Grant A | 11.0K | $0 |
| Jun 4, 2026 | Anand Mehra | Grant A | 42.4K | $0 |
| Jun 4, 2026 | Maxine Gowen | Grant A | 11.0K | $0 |
| Jun 4, 2026 | Maxine Gowen | Grant A | 42.4K | $0 |
| Jun 4, 2026 | Vincent Milano | Grant A | 11.0K | $0 |
| Jun 4, 2026 | Vincent Milano | Grant A | 42.4K | $0 |
| Jun 4, 2026 | Andrew N Schiff | Grant A | 11.0K | $0 |
| Jun 4, 2026 | Andrew N Schiff | Grant A | 42.4K | $0 |
| May 1, 2026 | Jesse Wayne Hall | Exercise M | 36.4K | $0 |
| May 1, 2026 | Jesse Wayne Hall | Other F | 9.3K | $41.1K |
| May 1, 2026 | Jesse Wayne Hall | Exercise M | 36.4K | — |
| Apr 23, 2026 | Braden Michael Leonard | Sell S | 300.0K | $1.4M |
About ACRS insider trading
This page tracks insider transactions for Aclaris Therapeutics, Inc. (ACRS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.